CorePharma launches generic Ritalin

MIDDLESEX, N.J. — CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis. Methylphenidate is intended for the treatment of narcolepsy and attention deficit disorders.



The drug is available in 5-,10- and 20-mg strengths. Methylphenidate immediate release tablets had U.S. sales of approximately $243 million as of December 2013, according to IMS Data.